<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<atom:link href="http://allterranews.com/news_xml/psoriasis.xml" rel="self" type="application/rss+xml"></atom:link>
<title>News - Psoriasis</title>
<link>http://allterranews.com</link>
<description>allterranews.com</description>
<language>en</language>
<copyright>Copyright (c) 2008-2026 </copyright>
<ttl>5</ttl>
<pubDate>Mon, 15 Jun 2026 21:21:38 +0200</pubDate>
<lastBuildDate>Mon, 15 Jun 2026 21:21:38 +0200</lastBuildDate>
<generator>allterranews.com</generator>
<docs>http://allterranews.com</docs>
Error connecting to the database.<item>
<title>Secukinumab and ixekizumab in psoriasis: Considerable added benefit for certain patients</title>
<link>http://allterranews.com/news/54/71039/Secukinumab-and-ixekizumab-in-psoriasis-Considerable-added-benefit-for-certain-patients.html</link>
<description><![CDATA[There were notably more remissions with Secukinumab and ixekizumab than under the comparator therapies for psoriasis. In future, the analysis of symptoms should not be limited to improvements at one time point.]]></description>
<category>psoriasis</category>
<pubDate>Fri, 5 Nov 2021 22:38:19 +0100</pubDate>
<guid>http://allterranews.com/news/54/71039/Secukinumab-and-ixekizumab-in-psoriasis-Considerable-added-benefit-for-certain-patients.html</guid>
</item>
</channel>
</rss>